je.st
news
Tag: immunotherapy
IPO-bound Aduro snags Big Pharma cancer immunotherapy deal
2015-03-30 11:22:11| Biotech - Topix.net
Tiny Aduro Biotech Inc. hopes to put the STING on cancer with a potential $750 million deal between the Berkeley company and drug giant Novartis AG. The deal centers on experimental synthetic small molecules, developed by Aduro, that could be the latest weapon in the hot field of cancer immunotherapy.
Kleiner Perkins's Beth Seidenberg Says Immunotherapy Is Biotech Powerhouse
2015-03-24 05:50:52| Biotech - Topix.net
Investing in biotechnology is known to be tough, as startups often face years of development time, clinical trials and regulatory work before maturing to the point where they can offer returns for the investors. But Kleiner Perkins Caufield & Byers recently bucked that trend, reaping well over 10 times what it put into immunotherapy company Flexus Biosciences Inc. in less than a year and a half.
Tags: beth
kleiner
biotech
powerhouse
Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology
2014-12-11 14:21:39| Biotech - Topix.net
Advaxis, Inc. , a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its Lm -LLO immunotherapy technology is featured in an article in the December 2014 issue of Nature Biotechnology . Entitled " Listeria vaccines join the checkpoint frenzy," the article explores the potential of the Listeria bacterium as a vector to enhance an anti-tumor response given its ability to induce powerful innate and adaptive immune responses.
Tags: featured
nature
biotechnology
immunotherapy
Roche, Merck extend immunotherapy fight to breast cancer
2014-10-18 04:23:46| Biotech - Topix.net
Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumors to another cancer type. Early clinical results with Roche's drug, known as MPDL3280A, in so-called triple negative breast cancer will be revealed at the Dec. 9-13 San Antonio Breast Cancer Symposium, the firm said after announcing third-quarter results.
Tags: fight
cancer
extend
breast
Compugen Discloses New Results For Novel Target Candidate For Cancer Immunotherapy
2014-10-01 14:07:35| drugdiscoveryonline Home Page
Compugen Ltd. recently disclosed results from recent studies further confirming CGEN-15049 as a promising target candidate for cancer immunotherapy. These recent studies evaluated the function of this Compugen-discovered immune checkpoint candidate on immune cells derived from the tumor environment of melanoma patients
Tags: results
target
cancer
candidate